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Abstract 5 
The delivery of materials for genetic engineering with transitory activity constitutes a promising field in biology and medicine with 6 
potential applications in the treatment of disease, from cancer and infectious diseases to inheritable disorders. The possibility to7 
restore the expression of a missing protein, the potential correction of the splicing of defective genes, or the silencing or8 
modulation of the expression of other genes constitute powerful tools that will have a great impact in the future of biology and 9 
medicine. Impressive progress has been made in the last decade, with several products reaching the market as novel technologies 10 
for gene editing emerge. However, the transference of these technologies to functional therapies is hindered by the suboptimal11 
performance of vehicles in capturing, protecting and delivering the corresponding nucleotide cargoes with safety and efficacy.12 
Chemistry and the chemical sciences will play a key role in the development of the innovative synthetic materials that will13 
overcome the upcoming challenges of the next generation gene delivery therapies and protocols. In this review we address the14 
newest chemical advances in the production of materials at the forefront of nucleotide cell delivery and gene therapy.15 
1. Introduction 16 
Chemistry and molecular biology have always been involved in the development of new technologies with potential 17 
therapeutic applications. DNA automated synthesis1 has been essential for PCR2, or site-directed mutagenesis3. These 18 
have allowed the generation of optimized fluorescent proteins4, phage display technology5, unnatural amino acids 19 
incorporation into proteins6, catalytic antibodies7,8 and synthetic genomes9–11. Among all of these discoveries and 20 
techniques, genetic engineering and gene therapy constitute one of the most promising technologies for the treatment 21 
of disease and for the future of human health12–14. The use of nucleic acids as therapeutic agents to repair a protein 22 
deficiency or to modulate gene expression has a great potential not only for the treatment of inherited disorders, but 23 
also in the treatment of acquired diseases through their utilization as DNA vaccines, antiviral therapies and cancer 24 
immunotherapy13 (TABLE 1). However, the growth of the expectations in gene therapy and medicine have 25 
sometimes been dramatically crushed by the delivery problem15. Nucleic acids are negatively charged and are 26 
occasionally very unstable molecules and thus their intracellular delivery, at the right place at the right moment, still 27 
constitutes a challenge for synthetic chemistry, materials science and biotechnology. 28 
A gene vector has to overcome different barriers before the successful delivery of its cargo (FIG. 1; TABLE 2). First, 29 
the nucleotide cargo should be protected from degradation, which is usually achieved by complexation or 30 
encapsulation in different structures16. The size and charge of these complexes has to be controlled as it affects uptake 31 
efficiency and bio-distribution, as too large or too small particles can be cleared by the mononuclear phagocyte 32 
system, the liver or the kidneys16. In systemic delivery, molecules larger than individual oligonucleotides cannot 33 
cross the endothelial barrier except for tissues with fenestrated or leaky vasculature17. Improving carrier selectivity by 34 
conjugation of the vector with targeting molecules can increase selectivity towards targeted cells increasing uptake 35 
and decreasing off-target effects17. Finally, vector particles have to translocate the plasma membrane, avoid 36 
endosomal entrapment and, in some cases, cross the nuclear envelope16. Moreover, the nucleotide cargo has to be 37 
released from the transported complexes to be free to interact with its target or be recognized by the cellular elements 38 
required for silencing, transcription or translation. Therefore, the delivery efficiency is not only a question of plasma 39 
membrane translocation and cellular internalization. The ideal gene carrier should be able to deliver different nucleic 40 
acids, protect the cargo from nucleases, avoid fast clearance, toxicity, and immune detection, prevent non-specific 41 
interactions with proteins and non-target cells, reach the cells of interest, escape the endosome, release the cargo and, 42 
when necessary, transport the cargo into the nucleus (TABLE 2)16,18,19. This is obviously not a simple task for 43 
synthetically scalable materials but the latest achievements in the field point to a promising future for the wide variety 44 
of non-viral vectors. 45 
Viruses function as natural gene carriers as they are able to bind the cell membrane, internalize in the cell, and escape 46 
the endosome to reach the cytosol. As viruses survival requires the efficient delivery of their own genetic material 47 
into cells, they have been artificially manipulated for therapeutic gene transfection20,21. Therefore, some modified 48 
viral vectors have been approved for the treatment of human disease, such as Glybera for lipoprotein lipase 49 
deficiency22, Gendicine for cancer treatment23, or Luxturna for retinal dystrophy24. However, viruses and derived 50 
materials present drawbacks, mainly related with their low cargo capacity and their immunogenicity that can cause 51 
fatal adverse reactions or abrogate their activity, or require additional immunosuppresive therapy14,25. Furthermore, 52 
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the limitations in the large-scale production of viruses and their potential to induce undesired insertional mutagenesis 53 
strongly complicates their real applicability in gene therapy. For instance, Glybera has been withdrawn from the 54 
market due to the high production costs and lack of demand26. 55 
The combination of synthetic chemistry and molecular biology has been widely explored for the development of 56 
artificial carriers that could accomplish efficient and selective intracellular gene delivery18,27–30. Traditional non-viral 57 
vectors showed low efficiency due to low cell selectivity as well as endosomal entrapment. Additionally, most of the 58 
delivery studies are performed on monolayers of immortal cell lines that usually contain alterations in DNA/RNA 59 
sensing or survival pathways, which can overestimate their efficiency when transferred to in vivo31. Nevertheless, 60 
impressive conceptual advances in synthetic gene vehicles have emerged in the last few years and several compounds 61 
have shown good activity, not only in vitro but also in vivo. Nucleotide chemical modifications have delivered a new 62 
set of artificial nucleic acid analogues with higher stability, improved activity and lower immunogenicity32. 63 
Additionally, the current covalent and supramolecular synthetic tools allow the preparation of an unlimited number of 64 
new compounds that can be applied for the delivery of bioactive nucleotides. Nowadays, several formulations for 65 
gene-based therapies are reaching the clinic33. Although viral vectors predominate in the medical applications of gene 66 
therapy34, synthetic vectors are becoming a real alternative in nucleotide-mediated therapeutics. For instance, naked 67 
antisense phosphorothioates have been recently approved for human use35, non-viral siRNA delivery systems are 68 
being tested for cancer treatment36,37, and Patisiran, a lipid nanoparticle for the delivery of siRNA for the treatment of 69 
hereditary transthyretin-mediated amyloidosis, has recently finished phase 3 studies38. This review will address the 70 
latest advances in non-viral gene delivery and we have sorted these synthetic carriers according to their chemical 71 
nature in order to highlight the importance of their molecular structure and connect this structural information to its 72 
particular functional application (TABLE 2).  73 
Cargo Description Site of Activity Function 
Plasmid 
Minicircles 
Large circular dsDNA molecules (several 
kb). Minicircles are usually smaller (no 
bacterial backbone). 
Need to reach the nucleus to be transcribed. 
Half-life in serum: 10-20 min200. 
Active in cells: some constructions can be 
active for months or years19. 
Nucleus 
Expression of proteins to restore a 
function or to develop an immune 
response against it. 
Expression of regulatory RNAs. 
Some risk of insertional mutagenesis by 
recombination with cellular DNA. 
mRNA 
Replicon RNA 
Large ssRNA molecules: several kb, 
typically mRNA < 10 kb; replicon > 10 kb 
(includes gene sequence and non-structural 
replicase genes). 
Secondary structure may impact translation 
efficiency28 
Half-life in serum: seconds201 
Active in cells: from minutes to days202 
Cytosol 
Protein expression to restore function or 
to develop immune response against it.  
Replicon self-amplifies and extends the 
time protein is being expressed. 






Short DNA, RNA or analogues (15-30 nt) 
Half-life dependent on the chemistry of the 
backbone. 
Cytosol/Nucleus 
Mask alternative splice sites to produce 
the desired mRNA isoform (splice 
correcting oligonucleotides). 
Degradation of mRNA after forming 
DNA/RNA duplexes by RNaseH 
(antisense oligonucleotides). 
Inhibition of mRNA translation by 





Short (~21-22 bp) 
Half-life in serum: minutes, but it can be 
increased with backbone modifications203 
Active in cells: from days to months, 
depending on the mechanism of action188 
Cytosol/Nucleus 
Directs RISC complex to specific 
mRNAs for degradation (siRNA, 
cytosolic) 
Induces long-term silencing by DNA 
methylation (siRNA, nucleus). 
Regulates mRNA stability or translation 
(miRNA, cytosolic). 





Short (~50-150 nt), typically with 
complicated secondary structures. 
Half-life dependent on the chemistry of the 
backbone 
Cytosol/Nucleus 
Nucleic acids with enzymatic activity, 
usually used as site specific nucleases. 
Composed of a single strand of DNA 
(DNazymes), RNA (RNazymes), or 
multiple strands (MNazymes).  
Table 1. A brief description of the nucleic acids cargos mentioned in the text.  74 
Barrier Strategy Examples Ref 
Nuclease 
degradation 
Backbone modification PS bonds and 2’ modifications to reduce hydrolysis 35,39–43 
Covalent attachment of 
molecules 
PEG brushes (pacDNA) 56,57 
Non-covalent interactions Masking of siRNA by dsRNA binding proteins 77,78 
Inhibitory local high salt concentration in SNAs 185–187,190–193 







Nucleic acid nanoparticles DNA or RNA nanoparticles generated by RCA or RCT. 58,59 
Covalent attachment to 
polymers or nanoparticles 
PEG-Brushes (pacDNA) 56,57 
Spherical nucleic acids 185–187,190–193 
Increased affinity for 
nucleic acids 
Modification of peptides with guanidiniocarbonyl pyrrole  
Polymer modification with zinc dipicolylamine 138 
Improved encapsulation 
methods 
Enhancing encapsulation efficiency of exosomes by 
cholesterol modified siRNA 
126,127 
High-yield encapsulation of siRNA in silica nanoparticles 194 






Increasing circulation time Enhancing interaction with albumin or antibodies 79–83 
Reducing toxicity Degradable nanoneedles to reduce inflammatory response 67 
Avoiding immune recognition of VLPs by shielding with 
polymers 
74 
Slow release of polyplexes from silica nanoparticles. 195 
Fluorination of polymers and dendrimers 145–147 
Targeting to the desired 
cells or tissue 
Recognition of membrane proteins by aptamers 49–51,58,119 
Recognition of membrane proteins by antibodies 82,83 
Recognition of ASGPR by tri-antennary-N-acetyl 
galactosamine 
52–54 
Spatial control of the delivery by using ultrasound 
triggered release of microbubbles or liposomes 
68–70 
Targeting peptides (RGD) 130,131,182 
Modification of the natural target of VLP and exosomes 
by surface modifications 
73,75,76,125 
Recognition of specific cells with artificial modifications 107,109 
Cellular 
uptake and 
release of the 
cargo 
Backbone modifications Gymnosis of phosphorothioate nucleotides 35,39–43 
Esterification to facilitate membrane crossing 48 
Endosomal escape Physical methods 66,67 
Taking advantage of viral capsid proteins in VLP 73,75,76 
Avoiding endocytic pathways (peptide CLIP6) 88,89 
Protonable peptides, foldamers and dendrimers 84,94–96,152 
Ionizable lipids 115,116,118 
Topology mediated fusion 110–113 
pH triggered disassembly 130–136,150 
Fluorination of polymers and dendrimers 145–147 
Cargo release Disulfide bonds 60,138,139,147 
Acid labile linkers 61,150 
Hydrazones 97–99,155 
pH-triggered disassembly 133,135–137,191 
Hyaluronidase mediated 140 
ATP-triggered disassembly 141–143 
Self-degrading polymers 144 
Fluorination of polymers and dendrimers 145–147 
Nuclear membrane Electroporation and deformation 66 
Incorporation of peptides with NLS sequences 165,188 
Table 2. Summary of the barriers for gene delivery and the strategies used by some of the non-viral gene 75 
carriers discussed in the text. 76 
 77 
 78 
Figure 1. Different synthetic materials and current challenges for efficient intracellular gene delivery. The 79 
successful delivery of a functional nucleic acid requires overcoming important biological barriers. An initial 80 
condensation of the nucleotide cargo in particles of the right size and charge for delivery also contributes to the 81 
protection of the cargo against ubiquitous nucleases. The endothelial barrier, the hepatic and renal clearance, and the 82 
accumulation outside the target tissue might hinder the bioavailability of the therapeutic nucleotide in the in vivo 83 
systemic delivery. To reach its final intracellular destination, nucleotide vehicles have to cross the plasma membrane, 84 
escape from the endosome and cross the nuclear membrane, if necessary, for their activity. 85 
2. Non-viral delivery methods  86 
2.1. Artificial “self-delivering” oligonucleotides 87 
Nucleotide chemical modifications. The activity and specificity of bioactive oligonucleotides depends mostly on 88 
their base sequence, while the biopolymer backbone usually plays a structural role. Therefore, nucleotides can 89 
tolerate the introduction of certain modifications on their structure that can improve their stability and uptake 90 
efficiency without affecting the recognition of its target. The chemical structure of oligonucleotide-based drugs has 91 
been in a state of permanent evolution to optimize their delivery and clinical applications32. Synthetically modified 92 
antisense oligonucleotides (ASOs) include, among others, phosphorothioate nucleotides (PS) in combination with 93 
locked nucleic acids (LNAs)39, tricyclo-DNA oligomers (tcDNA)40, 2'-O-(2-Methoxyethyl)-oligonucleotides (2'-O-94 
MOE)41 or 2'-deoxy-2'-fluoroarabinonucleotides (2'-F-ANA)42 (FIG. 2a). The substitution of the oxygen for a sulphur 95 
atom in phosphorothioate-modified antisense oligonucleotides (PS-ASOs) strongly reduces their nucleolytic 96 
degradation. The spontaneous uptake, or gymnosis, of these stabilized single stranded nucleotides has been observed 97 
both in vitro and in vivo39 and a number of formulations of phosphorothioate oligonucleotides have been approved for 98 
human use35, such as Fomivirsen for the treatment of cytomegalovirus retinitis43, or Mipomersen for homozygous 99 
familial hypercholesterolemia41. The inclusion of additional hydrophobic carbon atoms, between the C5' and C3' 100 
positions of the nucleotide of a phosphorothioate tricyclo-DNA (tcDNA), triggered its self-assembly into 101 
nanoparticles with a suitable size (40-100 nm) for in vivo delivery, and therapeutic improvement on a mouse model of 102 
Duchenne’s muscular dystrophy40. However, nucleotide chemical modifications can sometimes give rise to adverse 103 
effects such as complement activation, trombocytopenia, increased off-target interactions, or intrinsic toxicity of the 104 
corresponding metabolites44. Particularly, modifications that increase nucleotide hydrophobicity at the 2' position 105 
such as in 2'-fluoro-modified phosphorothioate-ASOs45 and phosphorothioate-LNAs46 have been shown to be 106 
hepatotoxic in mice. Intriguingly, less hydrophobic modifications like in 2'-O-MOE (2'-O-(2-methoxyethyl)) or in 107 
constrained 2'-O-ethyl nucleotides did not show the same effect45. However, there is growing evidence that this 108 
toxicity, probably due to an increased affinity of these nucleotides towards the hepatic proteins, can be controlled by 109 
sequence design optimization46. 110 
Charge reduction. The highly negatively charged phosphate backbone of nucleic acids blocks their interaction with 111 
the anionic components of the membrane and hinders its crossing of the non-polar membrane47, a situation that 112 
prevents the uptake of therapeutic oligonucleotides. The phosphate charges can be reduced by esterification and 113 
phosphotriester formation. The modification of the nucleotide phosphate, with the S-acyl-2-thioethyl (SATE) moiety, 114 
was optimized for 2' modified nucleotides (2'-F or 2'-O-Me) by employing the mild basic-sensitive phenoxyacetyl 115 
protecting group, which avoids phosphotriester hydrolysis at the nucleobase deprotection step. Although it cannot be 116 
applied to the whole sequence due to duplex destabilization, this esterification strongly increased the nucleotide 117 
bioavailability by binding to serum albumin. Additionally, fusion to cell penetrating peptides (CPPs) or glycan 118 
moieties (i.e. tris-N-acetylgalactosamine) enhanced the cellular uptake of the resulting hybrid oligonucleotides48. This 119 
elegant strategy allowed the high yield production of neutral siRNA derivatives (siRNN), in which the artificial 120 
thioester can be de-caged by cytosolic thioesterases to regenerate the original fully functional siRNA inside cells48 121 
(FIG. 2b). 122 
Programmable hybridization. The predictable and programmable folding of nucleotides can be employed to control 123 
the presentation of functional nucleotides and cell targeting sequences. This concept has been applied in gene targeted 124 
delivery by generation of active oligonucleotide/targeting aptamer chimeras such as aptamer-siRNA or aptamer-125 
miRNA chimeras49 (FIG. 2c). Analogously, a Y-shaped RNA scaffold containing anti miR-21 was combined with an 126 
EGFR aptamer, and the resulting chimera showed promising activity against breast cancer50. The programmable 127 
sequential recognition of a nanovehicle by two aptamers that are bound to two different cell receptors was employed 128 
for targeted gene delivery. The interaction of the nanovehicle with the first aptamer, bound to a cell surface receptor, 129 
cleaves a DNA loop by reconstitution of a MNAzyme. After this cleavage, a hybridization sequence of the 130 
nanovehicle is exposed and presented to the second aptamer that is bound to a different cell receptor. Hybridization 131 
with this second aptamer anchors the DNA nanovehicle to the membrane and enables specific endocytic 132 
internalization only in the cells where both receptors are present51. In addition to aptamers, fusion to other ligands can 133 
also be applied to trigger specific receptor-mediated endocytosis. The conjugation of antisense oligonucleotides or 134 
siRNA to tri-antennary-N-acetyl galactosamine is a widely used strategy for the targeted delivery to the hepatic 135 
asialoglycoprotein receptor (ASGPR)52–54 (FIG. 2c). The attachment of this particular glycan has also been confirmed 136 
to reduce the toxicity of the oligonucleotide conjugates55. PEG brushes have been also connected to antisense DNA 137 
(pacDNA) to increase the stability of the bioactive nucleotide against nucleases and facilitate its cellular uptake by 138 
endocytosis56,57 (FIG. 2d). Larger single stranded DNA or RNAs, generated by rolling circle amplification or 139 
transcription techniques58,59, can fold into globular structures or “nanoflowers” (FIG. 2d). These nanoassemblies can 140 
include aptamer sequences for tumour targeting and DNAzymes to silence specific genes required for cell survival58. 141 
Similar stimuli-responsive RNA nanoparticles have been recently developed to release multiples copies of siRNA 142 
inside the cell59. These cleavable RNA nanoparticles consist of a long ssRNA containing repetitions of a siRNA 143 
antisense strand hybridized with chimeric DNA-RNA sense strands. These DNA/RNA duplexes were coated with a 144 
glutathione sensitive chitosan polymer for delivery and they were cleaved inside the cell by the cellular RNaseH59. 145 
Dynamic covalent linkers. Attaching large structures to a nucleotide cargo may impair its biological activity. 146 
Covalent dynamic linkers (i.e. disulfide) can be used to connect the nucleic acid and the non-viral vehicle. These 147 
dynamic linkers can be cleaved by external stimuli (i.e. proteases, pH changes, reducing agents) and thus release the 148 
intact nucleic acid material at the suitable tissue or intracellular location. A multifunctional cationic amphipathic 149 
polymer can be grafted, via pH or protease sensitive linkages, to PEG and N-acetylgalactosamine pendants and 150 
connected to a siRNA cargo by a disulfide bond60. In the first step, the protease or pH-mediated cleavage restored 151 
ligand targeting and membrane interaction and, once inside the cell, the cleavage of the disulfide bonds triggered 152 
cargo release60. In a different conceptual strategy, nucleic acids that  are recognised by a polypeptide sequence can 153 
function as simple carriers for the delivery of transcription factors for gene expression regulation. In DNA assembled 154 
recombinant transcription factors (DARTs), the nucleic acid acts as a simple carrier and it can be decorated with 155 
glycan residues via a dynamic acetal linker that after hydrolysis unmasked hydrophobic endosomal disrupting 156 
domains to facilitate cargo delivery (FIG. 2e)61. 157 
 158 
Figure 2. Modifications for self-delivering oligonucleotides. a) Chemical modifications of nucleotides for 159 
gymnotic delivery. These modifications usually involve a phosphorothioate backbone (left) combined with additional 160 
modifications of the ribose, such as those pictured here. b) Phosphotriester modification reduces the negative charge 161 
of the oligonucleotide and can be reversed by the activity of cellular thioesterases, to get the natural phosphodiester. 162 
c) Examples of delivery systems that exploit cellular interaction for uptake, such as receptor-binding aptamers or 163 
glycan moieties attached to siRNA. d) Formation of globular structures, by the folding of long ssDNA or ssRNA 164 
strands obtained by rolling circle amplification or transcription (RCA or RCT) that can contain aptamer sequences or 165 
multiple repetitions of the active sequence, or by attachment of polymeric brushes that turn antisense oligonucleotides 166 
into compact particles. e) An example of the pH-sensitive dynamic linkers found in DARTs. 167 
2.2. Delivery assisted by physical methods 168 
The efficiency and low cost of physical gene transfection has recently triggered a rebirth of this field. Although with 169 
certain limitations for in vivo applications, excluding cutaneous treatment62 or local hydrodynamic gene delivery to 170 
liver or muscle63, physical methods can be very useful for ex vivo gene therapy. In ex vivo therapies, patient cells are 171 
removed, modified (i.e. transfected) under in vitro conditions and then reinfused into the patient. Electroporation, 172 
osmotic shocks or microinjection allow direct delivery of the oligonucleotide to the cytoplasm or nucleus, 173 
circumventing any endosomal pathway and/or nuclear membrane barrier64, because of the transient extensive 174 
disruption of the plasma and nuclear membranes. However, this aggressive technique can lead to severe cellular 175 
damage and new technologies are being developed to allow a better control of the degree of membrane disruption64. 176 
Indeed, physical gene delivery is currently in the pipeline for therapeutic applications such as cancer immunotherapy 177 
by chimeric antigen receptors (CAR), in where the T-cells of a patient can be extracted, physically transfected ex vivo 178 
and the new reprogrammed T-cells re-injected into the same patient to seek and destroy the tumour65. Recently, the 179 
combination of electroporation and microfluidic cell deformation has been explored for high throughput plasmid, 180 
mRNA or protein delivery66. The application of nanoneedles in drug and gene delivery is generally associated with 181 
inflammation62 which can be useful for vaccination but undesirable for other purposes. Biodegradable porous silicon 182 
nanoneedles have recently been developed, which increases their in vivo tolerance and safety67, and extends their 183 
potential applications. The collapse of gas-filled microbubbles, under target-directed ultrasound, was applied in 184 
systemic delivery of drugs68. However, the stabilization of microbubbles for DNA delivery usually requires 185 
microbubble functionalization with binary lipid mixtures to avoid perturbation of their acoustic properties68. A recent 186 
screening of these stabilizing lipids identified a single dimyristoyl cationic lipid branched with polyspermine and 187 
partially decorated with PEG. This single lipid formulation was able to deliver a miniplasmid to hepatocytes 188 
achieving long term gene expression69. Microbubbles can also be used for the targeted delivery of promiscuous 189 
cationic liposomes70. These plasmid loaded cationic liposomes can be functionalized with PEG and heparin to inhibit 190 
off-target uptake. The precise ultrasonic disruption of co-injected microbubbles triggered the local release of the 191 
liposomal contents70. Acoustic transfection, directly based on membrane disruption due to cavitation, can also 192 
achieve in vitro plasmid, mRNA or protein transfection with single cell resolution71. 193 
2.3. Carrier mediated 194 
2.3.1. Protein based 195 
Virus-like particles. Protein vehicles can also be employed to protect and deliver bioactive nucleotides. The 196 
encapsulation of nucleotidic cargo into a protein container is a ubiquitous strategy in nature in viruses and in higher 197 
organisms72. For instance, the Arc protein, evolutionary related to transposon’s gag protein, forms enveloped virus-198 
like particles that are able to deliver its own mRNA across neurons or the neuromuscular junction in mammals and 199 
insects72. Virus like particles (VLPs) that are reconstructed from proteins of the natural virus can encapsulate active 200 
oligonucleotides, inhibiting tumour growth by intracellular delivery of a suicide gene73. Interestingly, the strong 201 
immunogenicity of VLPs can be reduced by particle surface modification with polymers such as polynorbornene or 202 
polyethylenglycol74. Decoration of VLPs with targeting moieties can redirect these artificial capsids to other tissues, 203 
as was demonstrated by the attachment of transferrin or aptamers to polyomavirus VLPs75 or phages76. 204 
RNA binding proteins. dsRNA-binding domains are common in proteins of viral and non-viral origin and can be 205 
used for siRNA protection and delivery (FIG. 3a). A fusion protein composed of dsRNA-binding domains, from the 206 
protein kinase PKR, fused to a penetrating peptide sequence, was confirmed to deliver siRNA in hard-to-transfect 207 
cells and in vivo by intranasal inoculation77. To achieve an efficient intracellular siRNA delivery, the binding between 208 
the protein and the nucleotide has to be strong enough to protect the cargo, but it also has to be disrupted in the last 209 
step of the delivery process. A systematic study using high-affinity dsRNA binding proteins, derived from p19 of 210 
Carnation Italian Ringspot Virus¸ showed that, even for dissociation constants in the low pM range, the inhibitory 211 
binding-limit was not reached78. However, to achieve cytosolic delivery of the siRNA in this study a second pore 212 
forming Perfringolysin O protein was required to achieve endosomal escape78. 213 
Bioavailability enhancers. Association with certain proteins can improve cargo pharmacokinetics, as the bigger 214 
protein/cargo complexes can circumvent renal clearance and extend their serum half-life by the exocytosis-recycling 215 
pathway. The non-covalent binding of lipid modified oligonucleotides to albumin has been applied to enhance the 216 
bioavailability of siRNA79,80 and other antisense oligonucleotides81. Conjugation of nucleotides to antibodies can also 217 
provide improved pharmacokinetics and targeting capacities. A fusion protein composed of HIV specific F105 218 
antibody fragment and protamine, as a nucleic acid binding protein, was designed and confirmed to deliver a siRNA 219 
specifically to HIV infected cells82. After attachment of siRNA to antibodies, by redox sensitive disulfides in 220 
THIOMAB antibodies, no improvement in activity was found between a dynamic linker and a covalent connector. 221 
These results indicate that a reversible bond is not a prerequisite for activity83, as the linker is at the sense strand and 222 
it might not affect the antisense strand loading into the RISC complex. However, in all these examples of protein 223 
mediated delivery, the endosomal escape is usually the limiting factor and the addition of endosomolytic agents as 224 
pore forming toxins78 or CPPs77 is sometimes required to achieve efficient cargo delivery. 225 
2.3.2. Peptides 226 
Cell penetrating peptides (CPPs) have been extensively applied to the delivery of nucleic acids84,85, as covalent or 227 
non-covalent conjugates. Recent research on CPPs has focused on the development of new synthetic peptides for the 228 
delivery of artificial nucleotides (TABLE 3). Artificial PMO nucleotides have been conjugated to peptides of the Pip 229 
family86 and arginine-rich peptides87 that include non-proteinogenic aminoacids such as 6-aminohexanoic or β-230 
alanine. The resulting conjugates achieved therapeutic levels of cargo delivery in different animal models of muscular 231 
dystrophies86,87. The cationic amphiphilic CLIP6 cell penetrating peptide presents a D-proline at the middle of its 232 
sequence, together with a glutamic acid that disrupt its potential β-sheet secondary structure88. This “intrinsically 233 
disordered” peptide was able to reach the cell cytosol by a non-endocytic mechanism88 for PNA efficient delivery89. 234 
Amphiphilic peptide nanofibers, composed of a short cationic sequence and a β-sheet seed followed by a 235 
hydrophobic tail, can also be employed for slow release of antisense oligonucleotides in vitro90 and for localized 236 
siRNA delivery in vivo by stereotactic surgery91. Peptide nanofibrils92 or nanosheets93 can be implemented as 237 
enhancers of viral gene transfer92. These amyloids have the ability to concentrate and increase infectivity of 238 
lentiviruses, a very promising technology with multiple potential ex vivo applications92. In the RALA peptide, a 239 
variant of the amphiphilic GALA84, the protonation of glutamate residues prevents the anionic repulsion between 240 
peptide side chains and triggers helical folding. This secondary structure fluctuation allows membrane disruption at 241 
low pH and RALA mediated intracellular delivery of plasmids94 or mRNA95. Artificial non-peptidic foldamers have 242 
also emerged as biocompatible vehicles for gene delivery. Disulfide connected dimers of amphiphilic oligourea 243 
helical foldamers, equipped with imidazole and isopropyl moieties, were recently shown to deliver plasmid DNA in 244 
cells with low toxicity96. Dynamic bonds such as oximes or hydrazones are formed in mild aqueous conditions, with 245 
good yields, short reaction times and in a fully bio-orthogonal fashion. Combinations of cationic hydrophilic peptides 246 
with hydrophobic tails of different lengths and properties have allowed the straightforward screening and quick 247 
identification of new simple formulations for siRNA97, plasmid98 or Cas9 delivery99. The recently introduced 248 
guanidiniocarbonylpyrrole group can form four hydrogen bonds with the phosphate of nucleotides100 (FIG. 3b) and 249 
thus enhance the plasmid delivery capabilities of short peptides101. Cyclic peptides of alternating chirality102 250 
incorporating guanidiniocarbonylpyrrole can self-assemble into fibers that can also be applied in plasmid 251 
transfection100. Alternation of guanidiniocarbonylpyrrole and cyclohexylalanine afforded large amyloid peptide fibers 252 
that can be further processed with gold nanoparticles to obtain nanoparticles of the right size for cell transfection103. 253 
Another recent and interesting approach is the use of peptides with biological activity as carriers104. For instance, the 254 
peptide PepM, derived from a Dengue virus protein, reduces by itself the number of mitotic cells and can also be used 255 
for siRNA delivery in combined therapy104. 256 
Peptide Sequence Notes 
Pip686 RXRRBRRXRYQFLIRXRBRXRB X =  aminohexanoic acid, B = β-alanine 
Peptide B87 RXRRBRRXRRBRXB X =  aminohexanoic acid, B = β-alanine 
CLIP688,89 KVRVRVRVpPTRVRERVK p = D-Proline Cross directly the cell membrane. 
Lys-PA90 Lauryl-VVAGK Nanofibers forming peptide. 
PNF91 Palmitoyl-GGGAAAKRK Nanofibers forming peptide 





Derived from the Italian familial form of Alzheimer’s 
Aβ. 
Enhances retroviral infection 
RALA94,95 WEARLARALARALARHLARALARALRACEA Derived from GALA peptide. 
PepM104 KLFMALVAFLRFLTIPPTAGILKRWGTI 
Residues 45–72 of Dengue virus 2C protein. 
Perturbs Bcr-Abl1 signalling. 
Table 3. Selected examples of peptide sequences for gene delivery. 257 
 258 
2.3.4. Lipid based  259 
Enhancing membrane fusion. Lipofection has been one of the most popular methods of transfection since the 260 
discovery that cationic lipids spontaneously condense DNA and fuse with cell membranes105. Current efforts in this 261 
field are focused on enhancing the fusogenic properties of the liposomes and minimizing their toxicity. In most cases, 262 
membrane fusion of liposomes is optimized to overcome the endosomal entrapment, while direct fusion with plasma 263 
membrane and subsequent direct delivery in the cytosol has received much less attention106. Inspired by SNARE 264 
proteins responsible for vesicle fusion in cells, artificial liposomes exposing one of the peptides of a coiled-coil motif 265 
specifically delivered siRNA and splice correcting oligonucleotides in cells that were previously loaded with the 266 
corresponding coil counterpart peptide107 (FIG. 3c). The application of this methodology has allowed the preparation 267 
of different fusogenic peptide liposomes for the direct intracellular release of vesicular contents108. Cell surface 268 
engineering by ketone-containing lipids has been recently applied to cell transfection with the corresponding lipoplex 269 
containing bio-orthogonal reactive alkoxyamine functionalities109 (FIG. 3d). However, the in vivo application of these 270 
creative approaches will require the challenging selective ketone-lipid or coil modification of the target cells107,109. 271 
The lipid transfection helper DOPE bears two bulky oleyl hydrophobic tails giving rise to a conical shape lipid that 272 
tends to assemble into the less stable hexagonal phase instead of the lamellar phase adopted by other lipids with 273 
higher head to tail surface ratio110,111. The Safinya group recently demonstrated that inverse bicontinuous gyroid 274 
cubic nanostructures, confirmed by X-ray scattering, could also enhance fusion with the endosome membrane and 275 
efficiently deliver siRNA without the requirement of a high cationic charge112 (FIG. 3e). Although these cuboplexes 276 
were not able to transport longer DNAs, they can be further modified with PEG for additional stabilization without 277 
activity loss, pointing towards future in vivo applications113. 278 
Lipid nanoparticles engineering. Lipid nanoparticles can be modified by using mixtures of different lipids in which 279 
not only the lipid composition, but also the synthesis method, can have a great impact on the size, the biodistribution 280 
and the delivery efficiency114. Typically, they contain a pegylated lipid, cholesterol, a helper lipid and an ionizable 281 
lipid. The cross-reaction of alkylamines with alkylacrylates with different hydrophobic tails generated a library of 282 
ionizable lipidoids that were combined with cholesterol, DSPC and PEG-DMG to formulate nanoparticles for siRNA 283 
delivery. This strategy allowed the extraction of structural insights about ionizable lipid nanoparticles for endosomal 284 
escape and for in vivo delivery. The most effective formulations included lipidoids with three or more hydrophobic 285 
tails, secondary and tertiary amines and a particle surface pKa of around 5.5-7115. Recent studies on ionizable lipids 286 
also stressed the importance of tertiary amines and the steric constraints for the conformational switch of the lipids 287 
that triggers endosomal escape by changing the relative orientation of the hydrocarbon chains116 (FIG. 3f). The net 288 
surface charge of liposomes can alter their biodistribution, as shown by DOTMA and DOPE mixed liposomes that 289 
accumulated in the lung when having a positive charge or in the spleen as the negative charges increased. This 290 
property was exploited to deliver mRNA to dendritic cells for the development of mRNA vaccines against cancer117. 291 
In a similar strategy, lipid nanoparticles containing phospholipids, ionizable and PEG-modified lipids, cholesterol, 292 
and a lipopolysaccharide adjuvant, were loaded with mRNA and the subcutaneous injection of these liposomes 293 
triggered an immune response that could overcome the critical self-tolerance against auto-antigens required in cancer 294 
immunotherapy118. Thiol-conjugated lipids/aptamers can be also assembled into nanoparticles and employed in 295 
targeted delivery of siRNA to different tissues such as bone to improve osteogenesis119. Polydiacetylenic derivatives 296 
with protonable amine or imidazol groups can be crosslinked with UV light to generate interesting structures, such as 297 
nanomicelles120,121 or nanofibers122 that are suitable for plasmid and siRNA delivery. The clinical potential of lipid 298 
engineering is exemplified by Patisiran, a siRNA drug against hereditary transthyretin-mediated amyloidosis, which 299 
is delivered by lipid nanoparticles containing DLin-MC3-DMA38,123. 300 
Exosomes and Sterosomes. Exosomes are naturally produced vesicles containing lipids, proteins and nucleic acids 301 
that can act as natural carriers of proteins and nucleic acids. Generally, extravesicular engineering has been carried 302 
out by the loading of exogenous agents and by the genetic engineering of parental cells124. However, until recently 303 
the chemical modification of exosomes for gene delivery has been surprisingly overlooked. In an interesting 304 
biotechnological strategy, fusogenic liposomes were used to load the membrane of living cells with azide modified 305 
artificial lipids. The chemically modified exosomes produced by these cells can then be easily further functionalized 306 
by click chemistry, for example by conjugation with targeting peptides125. In recent examples, the loading of 307 
exosomes with synthetic oligonucleotides was simplified by the use of hydrophobic cholesterol-modified 308 
siRNA126,127. Despite their promising properties, the cellular origin of exosomes constitutes an important challenge in 309 
terms of their large-scale production with standard sizes and compositions. Sterosomes, cationic liposomes enriched 310 
in steroles and stearylamine, can provide a more stable alternative to phospholipid liposomes, as they are less affected 311 
by hydrolysis and oxidation128 (FIG. 3g). Sterosomes have been embedded in hydrogels for sustained noggin siRNA 312 
delivery to enhance osteogenic differentiation during bone regeneration128. 313 
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 315 
Figure 3. Peptide and lipid based delivery systems. a) dsRNA binding proteins can be used for the recognition and 316 
delivery of siRNA. b) Guanidiniocarbonylpyrrole (GPC), showing the four potential hydrogen bonds that can be 317 
established with the phosphate backbone. c) Mechanism of fusion enhancement between cellular membranes and 318 
liposomes, by exploiting the formation of coiled-coils of peptides present in the liposome carrier and the cell 319 
membrane target. According to the cartoon, the helical wheel representation of the coil of the vesicle (in blue) and the 320 
coil of the cell membrane (in red) include the following amino acids: hydrophobic (A, L, I in black), cationic (K in 321 
purple) and anionic (E in orange). d) Bio-orthogonal reaction between the alkoxyamine bearing lipids of the liposome 322 
vehicle and a cell membrane loaded with lipids exposing ketone groups. e) Structure of cuboplexes, whose topology 323 
allows membrane fusion without the requirement of a high cationic charge (reproduced with permission from REF. 324 
112; Copyright © 2010, American Chemical Society). f) Ionizable lipids contain a head with protonable groups and 325 
flexible bonds that allow conformational changes when the head is protonated. The conformational change induced 326 
by protonation in the lipid library synthesized by Viricel et al. is depicted. g) Sterosomes are alternatives to 327 
phospholipid liposomes prepared by mixing stearylamine with esteroles such as cholesterol and its derivatives. 328 
2.3.5. Polymers, dendrimers and micelles 329 
pH disassembly. Polymers can display, in a multivalent fashion, the functionalities that are required for membrane 330 
recognition, interaction and translocation. This structural versatility and the potential synthetic scalability turn 331 
synthetic polymers into one of the most promising artificial materials for gene delivery. The current research efforts 332 
in polymeric materials for gene delivery are focused on improving condensation of the cargo, the reduction of the 333 
toxicity and the enhancement of the endosomal escape. To achieve these challenging goals, new polymers have been 334 
designed to disassemble upon the exposure to external stimuli such as reducing agents, enzymes, light, temperature, 335 
and above all, pH. The cooperative pH triggered disassembly of poly(2-(diisopropylamino) ethylmethacrylate) 336 
(PDPA) offers an excellent conceptual advance for micelle disruption and cargo release at the tumour 337 
microenviroment129 (FIG. 4a). This concept was exploited in PDPA ultrasensitive pH co-polymers containing RGD 338 
peptide, PEG, and grafted with cationic lipid-like structures130,131. The resulting grafted nanoparticles showed a very 339 
narrow pH triggered disassembly at the pH of the early endosome that was employed for in vivo siRNA tumour 340 
targeted delivery130,131. In an analogous approach, the pKa of low uptake cationic micelles was tuned by adjusting the 341 
ratios of its components (PDPA and PDMAEMA). At the optimal pKa (6.8-7), an excellent siRNA delivery was 342 
observed even at low cellular uptake or in hard-to-transfect cells132. The pH-dependent aggregation of oligo-343 
ethyleneimines (OEI) was optimized by the attachment of different aromatic pendants, such as salicylate (SaOEI), to 344 
maximize the pH-triggered disassembly and cargo release of polyplexes with different nucleic acids133 (FIG. 4a). The 345 
pH-triggered dissociation of polyplexes can also be used to release a hidden membrane-lytic peptide to enhance 346 
nucleotide release134. This method avoided the membrane disruption until the complex reached the endosome and 347 
thus reduced the toxicity of the final formulation134. A different pH-triggered strategy to change polymer properties, 348 
from hydrophobic to hydrophilic, to trigger polyplex disassembly and plasmid delivery, explored the pH dependent 349 
cleavage of benzoic aromatic imines to generate cationic amines135. Charge altering releasable transporters (CARTs) 350 
are composed of oligo(carbonate-b-alpha-amino ester) and a lipophilic block. CARTs polymers lose their charge and 351 
self-immolate at cytosolic pH, by intramolecular amide formation and piperazines release, to efficiently deliver 352 
mRNA both in vitro and in vivo136 (FIG. 4a). Self-replicating alphavirus replicons are large RNA molecules that can 353 
sustain prolonged protein expression but they do not tolerate structural chemical modifications. To protect them from 354 
nucleases, these replicons can be formulated with cationic ionizable dendrimeric poly(amido amine) and pegylated 355 
lipids before intramuscular injection for their in vivo use as RNA vaccines137. 356 
Redox, enzymes and other strategies for polyplex disassembly. Several other strategies have been studied to 357 
trigger nucleotide release from polymeric formulations. The disulfide bond can also be exploited in polymers that 358 
disassemble in the reducing cytosolic environment. The transfection efficiency of branched PEI was enhanced by 359 
polymer disulfide functionalization with zinc dipicolylamine analogues, which increases vehicle DNA affinity, 360 
membrane binding and transfection efficiency138 (FIG. 4b). Pegylated polymers, carrying dithiolane rings for 361 
disulfide crosslinking, can be assembled into nanoparticles loaded with siRNA (FIG. 4b). These nanoparticles were 362 
decorated with tumour targeting peptides and showed virus-like cell attachment and “capsid uncoating” behaviour in 363 
the cytosol139. In a different enzymatic disassembly strategy, a core-shell artificial virus was prepared by covering a 364 
fluorinated cationic polymer and a DNA core with an outer shell made of a polymer of hyaluronan with PEG and R8-365 
RGD peptides. The degradation of this layered polyplex was mediated by the hyaluronidase overexpressed in the 366 
tumour environment, which exposed the particle core and allowed the in vivo delivery of problematic large 367 
plasmids140. Polyols, including siRNA, can be stabilized by reversible ester formation of the 2-cis-diols of the 368 
terminal ribose or other polymers with phenylboronate141. After uptake, these boronate-stabilized particles can be 369 
disrupted by the high levels of internal ATP triggering siRNA142 or plasmid release143 (FIG. 4b). In other cases, 370 
instead of a stimulus, timed degradation can be used to protect the cargo until cytosolic delivery. This is true in the 371 
case of poly(2-dimethylaminoethyl acrylate) (PDMAEA), a cationic polymer that slowly self-degrades into a 372 
negatively charged compound that repels its cargo for siRNA release144 (FIG. 4b). 373 
Fluorinated dendrimers and polymers. PAMAM perfluorinated dendrimers condensate plasmid DNA at very low 374 
N/P ratios, reducing its positive charge and thus lowering toxicity and increasing efficiency in the presence of 375 
serum145,146. Their hydrophobic and lipophobic properties reduce their membrane interactions and increase their 376 
ability to penetrate tissues and spheroids146. This intriguing principle was applied in bioreducible PEI micelles with a 377 
perfluorinated core that showed good activity in DNA delivery147. Polymer fluorination has also shown excellent 378 
potential for the delivery large plasmids140 and proteins148. 379 
Supramolecular chemistry and dynamic chemistry. Weak non-covalent bonds like electrostatic and hydrophobic 380 
interactions control the dynamic processes of nucleotide complexation, protection, membrane translocation and 381 
complex disassembly. Therefore, supramolecular chemistry and supramolecular templates are powerful tools to 382 
understand and to develop conceptually new non-viral vectors. Cyclodextrin-based carriers consist of a linear cationic 383 
polymer containing cyclodextrins that can complex with siRNA and then incorporate targeting and stabilizing 384 
moieties by supramolecular host-guest chemistry with adamantane conjugates36,149. This modular strategy originally 385 
developed by Mark Davis149 has been recently modified by using non-polymeric cyclodextrin with LMW PEI 386 
pendants that are stabilized with pH sensitive polyketal poly-adamantanes150 (FIG. 4c). Cyclodextrins polymers have 387 
also been recently used in tumour targeted combined therapy with a chemotherapeutic agent and plasmid DNA151. 388 
Amphiphilic polymers with a hydrophobic core, capped with dendronized dipeptides, enriched in aromatic tryptophan 389 
or pH responsive histidine residues, performed as good in vitro delivery vectors for siRNA152. However, 390 
cyclodextrins have recently showed toxicity problems in phase one clinical trials37.  The use of thiol click-chemistry 391 
allows the fast preparation of libraries of polyesters for siRNA delivery that can show selectivity to tumour 392 
cells153,154. Hydrazone-modulated polymers have also been recently introduced as a promising alternative to screen 393 
for polymer nucleotide vehicles. In this strategy, poly-hydrazides can be modified with different combinations of 394 
cationic and hydrophobic aldehydes to generate a library of amphiphilic polymers that can complex and deliver 395 
siRNA and plasmid in living cells155,156 (FIG. 4d). 396 
Combined therapies. In several recent examples, the polymer can also play an active role and contribute to an 397 
additional therapeutic function instead of acting as a mere carrier. PolyMetformin, derived from the anticancer and 398 
antidiabetic drug metformin (dimethyl biguanide), has the ability to complex siRNA while preserving its anticancer 399 
properties and it can be formulated with lipids and co-delivered into tumour cells157 (FIG. 4e). A dendronized 400 
dithiophene semiconducting polymer can also deliver a plasmid and trigger the expression of genes regulated by heat 401 
shock proteins by near infrared photothermal activation158. 402 
Glycan, protein and antibody conjugates. N-acetyl-D-galactosamine pendants have been incorporated in 403 
guanidinium polymers to enhance targeting and reduce toxicity in the transfection of HepG2 cells159. Similar 404 
behaviour has been observed in poly(glycoamidoamines) and PEI derived polymers that incorporate carbohydrate (D 405 
-glucaric acid) co-monomers160. These materials have been further modified by adding alkyl chains to obtain polymer 406 
brush materials loaded with siRNA, mRNA and lipids to produce nanoparticles with in vivo activity161. The 407 
introduction of alkyl chains to enable self-assembly with other hydrophobic compounds, such as pegylated lipids, has 408 
been applied to poly(β-amino esters) (PBAE), to generate nanoparticles to deliver mRNA to the lungs162. Another 409 
problem with mRNA delivery is that certain cationic carriers can mask the m7G cap at the 5’ end, blocking its 410 
recognition by cellular proteins and inhibiting mRNA translation. To improve translation initiation, mRNA can be 411 
pre-assembled with eIF4E, the protein involved in cap recognition, a technique that enhanced mRNA expression, 412 
both in vivo and in vitro163. Programmable self-assembly was exploited to prepare dendrimeric siRNAs that were 413 
efficiently complexed to PBAE polymers or branched and linear PEI164. PBAE polymers containing peptides with 414 
microtubule-associated sequences and nuclear localization signals were employed to overcome the limitation of 415 
crossing the nuclear membrane for plasmid delivery in non-dividing cells165. In a recent and extraordinarily 416 
promising approach, a plasmid DNA packed with this PBAE polymer was coated with poly(glutamic) acid fused to a 417 
targeting antibody and the resulting polyplex allowed in vivo reprogramming of T-cells with CARs for the treatment 418 
of a leukemia model165. 419 
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 421 
Figure 4. Polymeric approaches to gene delivery. a) Structures of pH-sensitive polymers. PDPA gets protonated at 422 
low pH and electrostatic repulsion disassembles the polymeric structure. Salicylic acid modification of 423 
oligoethyleneimine (SaOEI) reduces its affinity for nucleic acids at low pH and contributes to the disassembly of the 424 
polyplexes. CARTs are self-immolative polymers that degrade at pH higher than 7. b) Polymers that respond to other 425 
stimuli. Disulfide bonds can be used for disassembly in the reducing conditions of the cytosol, as in the case of zinc-426 
dipicolylamine modified PEI or dithiolane rings that can be introduced in the polymer sequence for crosslinking and 427 
stabilization of the nanoparticles. Cationic PDMAEA spontaneously degrades into the negatively charged 428 
poly(acrylic acid). ATP responsive polymers are based on the reversible interaction of phenylboronic acid with diols. 429 
c) Cyclodextrins can be incorporated into cationic polymers (left) and then modified with different compounds (PEG, 430 
targeting moieties...) using adamantane or another hydrophobic residue that interact with the cyclodextrin. 431 
Alternatively, individual cyclodextrins can be decorated with shorter cationic polymers for nucleic acid interaction 432 
and then assembled into larger structures using poly-adamantanes (right). d) Conceptual scheme for dynamic 433 
polyhydrazones. Dynamic hydrazide polymers can be combined with different aldehydes to afford cationic 434 
amphiphilic polyhydrazone for nucleotide delivery. (Reproduced with permission from REF. 155). e) Example of a 435 
polymeric nucleotide vehicle, polyMetformin, that presents intrinsic biological activity for combined therapy. 436 
2.3.5. Nanoparticles 437 
Carbon allotropes. The use of inorganic structures for plasmid delivery can be loosely tracked back to the 70s, with 438 
the development of the calcium phosphate co-precipitation method for DNA delivery into cells166. Since then, the 439 
nanoparticle field has evolved tremendously with substantial improvements being made in the characterization of 440 
nano-structures and the implementation of novel functionalities. Carbon nanoforms constitute promising materials for 441 
a range of diagnostic tools and biomedical therapies167. The potential toxicity of carbon nanostructures can be 442 
modulated by controlling the size and by modifying the surface of the nanoparticles, and thus chemistry plays a key 443 
role in turning carbon allotropes into biocompatible scaffolds167. In gene delivery, chemically functionalized carbon 444 
nanotubes (CNs) exploit their high aspect ratio to rupture or to slip through the lipid bilayer (FIG. 5a). The 1,3-445 
dipolar cycloaddition of carbon nanotubes with azomethine ylides can be employed to equip CNs with pendants of 446 
oligoethyleneglycol bearing terminal amines for the binding and delivery of DNA plasmids168. The carboxylic groups 447 
at the tips of oxidized CNs allow the attachment of ammonium and guanidinium dendrons by amide bond formation 448 
or click chemistry for siRNA complexation and delivery169. In an alternate approach to covalent modification, 449 
supramolecular hydrophobic interactions between CNs and lipid/PEG amphiphiles can also be employed to stabilize 450 
CNs in water and functionalize them by disulfide bonds with a siRNA cargo170. As the bio-distribution of CNs is 451 
influenced by their width171 or length172, this property can be exploited in targeted gene delivery172. Recent studies 452 
have shown that CNs have the ability to insert and cross the zona pellucida to deliver DNA into embryos without the 453 
requirement of individual manipulation173. Cationic fullerenes, such as the tetra(piperazino)fullerene epoxide, can 454 
efficiently condense and deliver a plasmid DNA with suitable low toxicity when used in vivo174. Polycationic 455 
fullerene hexakis-adducts have also been employed in plasmid transfection in vitro175. The ROS generation of 456 
fullerenes when excited by light can also be exploited to enhance the endosomal escape of siRNA for cationic dextran 457 
decorated fullerene vehicles176. Conjugation of CPPs to graphene oxide nanosheets reduces CPP toxicity and 458 
increases their activity for delivering pDNA and ASO, but not siRNA177. Nanodiamonds, a potentially more 459 
biocompatible carbon allotrope, can also be complexed to nucleic acids when decorated with amines178 or cationic 460 
polymers179–181 (FIG. 5b). The polymer pendants can be covalently attached by reaction with the carboxylated 461 
diamond surface179 or non-covalently conjugated by the electrostatic interactions between the cationic polymer and 462 
the anionic oxidized nanodiamond180,181. 463 
Metal Nanoparticles. The precise control of size, shape and the responsiveness to external stimuli are examples of 464 
the critical features that metal nanoparticles offer for biomedical applications. Additionally, the surface of metal 465 
particles can be straightforwardly functionalized with different bioactive and biocompatible targeting molecules. The 466 
thiol-gold linkage constitutes a simple and reliable method for the functionalization and modification of gold 467 
nanoparticles (FIG. 5c). Tissue-targeting of siRNA was achieved by the thiol-gold connection of metal nanoparticles 468 
and a block copolymer shell of poly-L-lysine-poly-ethylenglycol terminated by cyclic RGD peptides182 (FIG. 5c, 469 
left). The embedding of gold nanoparticles in hydrogels has been applied for colon cancer treatments by triple-470 
combination therapy (siRNA, drug and phototherapy). This multifunctional approach involved gold nanorods 471 
decorated with the Avastin antibody drug against VEGF and the colorectal cancer targeting peptide TCP-1. The 472 
nanorods were combined with gold nanospheres that were covered with siRNA and further functionalized with 473 
endosomolytic peptides for improved release183. Gold nanoclusters, prepared by glutathione and oligoarginine 474 
controlled Au3+ reduction, have been recently confirmed as excellent siRNA delivery vehicles for silencing the NGF 475 
gene against the challenging pancreatic cancer184 (FIG. 5c, middle). 476 
Spherical Nucleic Acids. The tightly packing of nucleic acids over the surface of nanoparticles gives rise to spherical 477 
shaped nucleic acids conjugates (SNAs) with interesting properties such as increased stability, enhanced affinity and 478 
the ability to transfect cells despite their negative surface charge due to potential interaction with scavenger 479 
receptors185. Different SNAs with gold cores have been used for the delivery of siRNA186–188 (FIG. 5c, right) or 480 
ribozymes189 into cells and animals. Topical wound application of SNAs made of oligoethylene glycol and siRNA 481 
(against GM3S) restores wound healing in diabetic mice186. SNAs surface modification with nuclear localization 482 
signal peptides (NLS) strongly enhanced nuclei siRNA delivery and induced long term gene silencing by RNA-483 
directed DNA methylation188. Although SNAs were initially assembled on gold nanoparticles185, further studies 484 
confirmed that their emerging properties were independent from the metal core. These findings triggered the 485 
emergence of more biocompatible cores such as DNA190, polymers (HOPO191), liposomes192 or other structures 486 
(POSS193). These “organic” SNAs have been successfully tested in siRNA delivery190–193. 487 
Porous particles. Mesoporous silica nanoparticles can achieve an extremely high siRNA loading capacity of up to 488 
380 µg/mg194. Such porous nanoparticles can be grafted with silanes (APTES, TEOS, MPTES) to modify their 489 
surface with amino and mercapto-groups (FIG. 5d). siRNA was then loaded by incubation in solution at low pH and 490 
the particles were finally covered with a block copolymer that was further modified with hydrophobic oleic pendants 491 
and terminal cysteines for cross-linking. The final silicon based porous ensemble achieved one of the highest siRNA 492 
delivery efficiencies described for silica nanoparticles194. A similar porous silicon platform can also be functionalized 493 
with aminopropyl-triethoxysilane (APTES), followed by amide connection with L-arginine and PEI. The pores of the 494 
cationic silicon carrier were loaded with siRNA, which was released in the form of polyplexes after silicon 495 
degradation. The prolonged slow release of these polyplexes reduced the toxicity of the formulation after systemic 496 
injection195. APTES grafted silica nanoparticles can be also functionalized by coordination with Ce3+ for further 497 
anchoring of branched PEI polymer. The resulting nanoparticles (SPA-Ce-PEI) delivered siRNA with higher 498 
efficiency than branched PEI alone196. Anionic mesoporous silicon nanoparticles, decorated with ICP (3-499 
isocyanatopropyltriethoxysilane), can be covered with cyclodextrin-grafted polyethylenimine. Doxorubicin was then 500 
encapsulated in the porous nanomaterial and the resulting nanoparticles were applied to the delivery of a cytotoxic 501 
drug and a siRNA against PKM2 in combined therapy against orthotopic breast tumours197. Metal organic 502 
frameworks (MOFs) constitute promising scaffolds for nucleotide encapsulation and delivery due to their controlled 503 
porosity. Zr4+ based MOFs were applied in combined therapy for the co-delivery of a cis-platin pro-drug and a 504 
siRNA198. In a similar strategy, cysteine grafted MOFs were filled with Se or Ru because of their ability to disrupt 505 
microtubules and act as antitumour agents. These MOFs were also loaded with VEGF siRNA by the coordination of 506 
the vacant Fe(III) sites with the nucleotide phosphates. The final nanoparticles were applied for combined therapy 507 





Figure 5. Nanoparticles for gene delivery. a) Covalent and non covalent modifications of carbon nanotubes for the 513 
delivery of nucleic acids. b) Surface functionalization of nanodiamonds for nucleic acid interactions. c) Delivery 514 
systems involving gold nanoparticles: a gold nanoparticle modified with a targeting motif (cRGD), PEG and 515 
polylysine for siRNA binding182; gold nanoclusters formed by reduction in the presence of glutathione and 516 
oligoarginine184 and an example of spherical nucleic acids186, in which siRNA is bound to the nanoparticle through a 517 
thiol group and decorated with PEG; d) Porous nanoparticles. Left: Metal-organic framework (MIL-101) 518 
incorporating Se or Ru ions for microtubule disruption and siRNA. Right: Surface functionalization of mesoporous 519 
silica nanoparticles. Coordination via Cerium of PEI (SPA-Ce-PEI), engraftment with APTES, or further 520 
modification of APTES with arginine and PEI to generate PCPS (polycation-functionalized nanoporous silicon) to 521 
obtain the positive charge necessary for nucleic acids interaction, or introduction of thiol groups with MPTES for 522 
crosslinking with other polymers. 523 
3. Discussion and outlook  524 
The increasingly active field of non-viral gene delivery holds great promise for the future of biotechnology and 525 
human health. The improvement of the synthetic methods has recently granted the access to new encouraging 526 
molecular entities and nucleotide modifications such as phosphotriesters48 or guanidiniocarbonylpyrrole groups101. 527 
Furthermore, the recent advances in microscopy and cell biology have allowed a higher level of understanding of the 528 
highly dynamic mechanism of uptake and escape of the cargo. These and other advances continuously assist and push 529 
chemists and material scientists to design and develop the next generation of non-viral carriers that can be sensitive to 530 
critical stimuli such as the specific pH required for disassembly132 or the optimal pKa of the lipid nanoparticles 531 
surface for enhanced uptake115. 532 
A clear trend for the future of the field will be the combination of new materials with novel formulation techniques. 533 
By blurring the barriers between different categories, the strength of each material can compensate the weakness of 534 
its counterpart and thus improve the performance of the final functional composite. Endosomolytic peptides buried in 535 
pH-sensitive micelles134, polymer-coated silica nanoparticles194 or peptide-lipid hybrids98 are just a few recent 536 
examples that outline potential directions of the field. Additionally, combined therapy emerges as an encouraging 537 
strategy in where the nucleic acid function is supplemented with other therapeutics such as bioactive polymers157 and 538 
co-delivery of cytotoxic agents197. Furthermore, the still mostly unexplored combination of chemically modified 539 
nucleotides and the next generation of synthetic transporters constitute a promising strategy to tackle the future 540 
challenges of synthetic materials at the forefront of gene delivery. Combinatorial libraries and high-throughput 541 
screening also constitutes an important and complementary technique compared to rational design, as it can identify 542 
structure-activity relationships and lead to unexpected results97–99,115,116,153-155. 543 
Importantly, the synthesis and formulation of the nanocarriers has to be scalable, reproducible and stable and 544 
although the field strongly demands new conceptual designs and strategies, the transference of these technologies to 545 
therapeutic applications will require a careful consideration of the synthetic scaling up process. In lipid particles, film 546 
hydration is sensitive to organic contaminants and in batch ethanol dilution homogeneous mixing is hard to achieve. 547 
Therefore, crossflow or microfluidics constitutes an excellent alternative for reproducibility and scalability107,109,112–548 
118,123. The standard electrostatic complexation of nucleotides with polymers or peptides requires a good control of 549 
mixing and thus concentrations, charge ratios and pH and ionic strength have to be carefully considered94,95,97–102,130–550 
133,136,145,146. Polyplex stability upon dilution is lower than for other formulations, although PEGylation might improve 551 
this situation. In gold nano-conjugates, salt reduction followed by ligand exchange or direct reduction with thiolated 552 
ligands can be potentially scaled up182–184,186–188. However, the election of the method in this case, will depend on the 553 
availability of the suitable thiolated ligands. Silica nanoparticles seem also promising scalable materials as they can 554 
be prepared by condensation of inexpensive silicates under different conditions194–197. 555 
It seems nowadays clear that not all in vitro results will work in vivo. Most of the in vitro experiments have been done 556 
in serum free conditions on immortalized cell lines that usually contain alterations that affect their ability to detect 557 
nucleic acids and enhance the cells tolerance to stress. These critical points for in vitro studies could lead to an 558 
overestimation of the delivery efficiency and an underestimation of the vehicle toxicity. Better in vitro models, such 559 
as primary cell cultures77,136,138, or spheroids80,146 may predict better the outcome of in vivo experiments, but they still 560 
lack the complexity of a living organism. In addition, the translation of these results to the clinic will always have to 561 
pass regulatory challenges, as all new formulations must be proven safe before further testing, and in this regard, 562 
formulations related to well established technologies, such as lipid-based carriers, will be in an advantageous 563 
position. So far, the most advanced methods in the race for clinical application34 of non-viral vectors are 564 
phosphorothioates, naked plasmid DNA, lipid-based carriers and, to a lesser extent, polymeric carriers34–38, which 565 
have already some examples approved35 or nearly approved38 for human use. The simplicity of the method of 566 
delivery of the naked cargo and the strong experience with liposomal-based drug delivery vehicles justify their 567 
predominance. On the other hand, non-biodegradable nanoparticles (i.e. carbon nanotubes, fullerenes, metal 568 
nanoparticles, etc.) may be problematic in the long-term, especially in cases where repeated administration may be 569 
necessary, as they tend to accumulate in liver and kidneys. To address this concern, there are several initiatives that 570 
try to replace the metal core of SNAs for biocompatible alternatives190–193. However, it is also possible that the 571 
therapeutic use of non-biodegradable nanoparticles might be restricted to cases in which the nature of the particle 572 
contributes to the treatment, as in photothermal therapy183.  573 
Despite impressive advances in the last decade, there are still considerable challenges that need to be met to help 574 
broaden the scope of potential future therapeutic applications of non-viral vectors such as vehicle bioavailability79–81, 575 
reduction of immune response32,74, balance of stability and release40–42,58,78,115 and endosomal escape95,132,135. In this 576 
regard, the growing number of synthetic materials for the efficient in vivo transfection of hard-to-transfect cells 577 
demonstrates the enormous power of chemistry and biology working together (TABLE 4). All these great advances 578 
help inspire new approaches to gene therapy and bring hope for the future of human health165. 579 
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Potential problems by unwanted 
protein interactions. 
Limited by the synthetic 
method; typically short. 
Yes, but modified 
nucleotides 
increase costs. 
Yes, by attaching 
ligands.  
Some approved for human use35,41 
Physical methods 
Delivery of the 
naked cargo. 
Microbubbles (~2-







For ultasound targeted 
microbubble disruption, potential 
liver damage.  
With degradable nanoneedles, 
less inflammation than with 
classical nanoneedles. 
From ASO/siRNA to pDNA. Yes 
Local administration 
with nanoneedles, or 
spatial control through 
target directed 
ultrasounds. 
Transfection of skin and muscle of 
mice with nanoneedles67. 
Transfection with ultrasound in 
mice68–70 




For VLPs, depends 
on the virus used.  
In other cases, 
soluble. 
Increased 
stability. Low toxicity 
Depends on the protein used: 
in viral capsid, several 
kilobases, for dsRNA binding 







By viral tropism, 
targeting ligands, by 
fusion to antibodies or 
by EPR (albumin). 
i.v.73,79–83 and intranasal77 
inoculation in mice. 
Peptides 
50 nm to several 
µm (fibers). 
Several days 
in serum. From low to moderately toxic. 
From ASO/siRNA to pDNA.  
In peptide-oligonucleotide 
conjugates, length is limited 
by the synthetic method. 
Yes, but in some 
cases synthesis 
can be expensive. 
With targeting 
sequences or ligands. 
i.c.91, i.v. 86,94, and intradermal95 
injection of mice. 
i.v., i.c. or i.m. in dogs87 





Low toxicity, except for highly 




can be hard to 
scale up. 
By EPR or with 
targeting ligands. 
i.v.115–117, s.c.118 and combined with 
hydrogels128 in mice; lipid 




From 10 nm 
(smallest 
dendrimers) to 






Most polymers are very 
biocompatible, but some toxicity 
issues have been observed 
(immune response, 
cytotoxicity...) 
From ASO/siRNA to pDNA. 
Yes, although 




By EPR,with targeting 
ligands or stimuli 
responsive motifs. 
i.c. 135, i.p.122, i.m.133,136,137, i.t.134,146, 
i.v.130,131,136,139,140,149,151,157,165 in 
mice. Some reached clinical trial 
strage36, but were retired because 
of adverse effects37. 
Nanoparticles 
From 20 nm 
(SNAs) to 60 µm 
(CNs) 
From hours to 
days 
In general, inert and with low 
toxicity, but hard to degrade in 
the body. Some carbon allotropes 
can be toxic depending on 
functionalization and 
contaminants from synthesis. 
From ASO/siRNA to pDNA. 
Yes, but 
influenced by the 
modifications. 
With targeting ligands, 
EPR, size... in some 
cases light stimulation. 
 
i.v.172,174,184,195,197,199, s.c.176 or 
topically in mice186; bovine 
embryo transfection173.  
Table 4. A brief summary of the different categories discussed on the text. * i.c.: intracranial, s.c.: subcutaneous, i.p.: intraperitoneal, i.m.: intramuscular, i.v.: intravenous. 581 
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